Effects of illness duration on cognitive performances in bipolar depression are mediated by white matter microstructure

Anxiety and DepressionBipolar Disorder

A Homer 1 gene variant influences brain structure and function, lithium effects on white matter, and antidepressant response in bipolar disorder: A multimodal genetic imaging study

Prog Neuropsychopharmacol Biol Psychiatry.

Benedetti F, Poletti S, Locatelli C, Mazza E, Lorenzi C, Vitali A, Riberto M, Brioschi S, Vai B, Bollettini I, Melloni E, Aggio V, Falini A, De Bartolomeis A, Colombo C

doi: 10.1016/

Anxiety and Depression

Changes in white matter microstructure after electroconvulsive therapy for treatment resistant depression

Int J Neuropsychopharmacol.

Gryglewski G, Seiger R, Baldinger-Melich P, Unterholzner J, Spurny B, Vanicek T, Hahn A, Kasper S, Frey R, Lanzenberger R

doi: 10.1093/ijnp/pyz059.

RECOMMENDED

Multiple SclerosisAnxiety and Depression

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders

Neurology.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease

doi: 10.1212/WNL.

Anxiety and DepressionBipolar Disorder

The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial

J Affect Disord.

Fotso Soh J, Almadani A, Beaulieu S, Rajji T, Mulsant BH, Su CL, Renaud S, Mucsi I, Torres-Platas SG, Levinson A, Schaffer A, Dols A, Cervantes P, Low N, Herrmann N, Mantere O, Rej S

doi: 10.1016/j.jad.2019.11.013.

Anxiety and Depression

Cognitive Performance in First-Degree Relatives of Individuals With vs Without Major Depressive Disorder: A Meta-analysis

JAMA Psychiatry.

MacKenzie LE, Uher R, Pavlova B

doi: 10.1001/jamapsychiatry.

Parkinson’s Disease

White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease

Neurology.

Bledsoe IO, Stebbins GT, Merkitch D, Goldman JG

doi: 10.1212/WNL.

Multiple Sclerosis

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

Neurology.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T

doi: 10.1212/WNL.

Aging and Cognitive Functions

Chemotherapy-induced cognitive impairments: White matter pathologies

Cancer Treat Rev.

Matsos A, Loomes M, Zhou I, Macmillan E, Sabel I, Rotziokos E, Beckwith W, Johnston IN

doi: 10.1016/j.ctrv.2017.09.010.

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia

JAMA Psychiatry.

Kochunov P, Coyle TR, Rowland LM, Jahanshad N, Thompson PM, Kelly S, Du X, Sampath H, Bruce H, Chiappelli J, Ryan M, Fisseha F, Savransky A, Adhikari B, Chen S, Paciga SA, Whelan CD, Xie Z, Hyde CL, Chen X, Schubert CR, O'Donnell P, Hong LE

doi: 10.1001/jamapsychiatry.

Related content

A Homer 1 gene variant influences brain structure and function, lithium effects on white matter, and antidepressant response in bipolar disorder: A multimodal genetic imaging study

Changes in white matter microstructure after electroconvulsive therapy for treatment resistant depression

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders

The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial

Cognitive Performance in First-Degree Relatives of Individuals With vs Without Major Depressive Disorder: A Meta-analysis

White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

Chemotherapy-induced cognitive impairments: White matter pathologies

Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia